NCT05206019View on ClinicalTrials.gov

Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

April 17, 2022

Study Completion Date

May 2, 2022

Conditions
HIV/AIDS
Interventions
DRUG

Albuvirtide

Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)

Trial Locations (1)

Unknown

The Second Hospital of Anhui Medical University, Hefei

Sponsors
All Listed Sponsors
lead

Frontier Biotechnologies Inc.

INDUSTRY